Introduction to the efficacy, effects and indications of Tislelizumab

Tislelizumab (Tislelizumab) is a humanized IgG4antiPD-1 monoclonal antibody drug independently developed by BeiGene. As an immune checkpoint inhibitor, it has shown good efficacy and safety in the treatment of various malignant tumors. This article will systematically introduce the efficacy and role of tislelizumab in terms of its pharmacological mechanism, main indications, clinical efficacy, and medication precautions.

1. Pharmacological mechanism of tislelizumab

Tislelizumab is an immunotherapy drug. Its mechanism of action is by blocking the programmed death receptor -1 (PD-1) and its ligands (PD-L1 and PD-L2), relieves the immunosuppressive state of T cells mediated by PD-1, thereby restoring the killing function of T cells. This mechanism allows the patient's immune system to recognize and attack tumor cells without being "misled" into normal tissue.

Different from other PD-1 inhibitors, tislelizumab was engineered through the Fc segment during research and development, which effectively reduces the interaction with macrophagesFcγR reduces the non-specific clearance of T cells, improves the efficacy and reduces the probability of adverse reactions. This feature makes tislelizumab highly competitive in multiple tumor treatment fields.

2. Introduction to main indications

As of2025, tislelizumab has been approved for multiple indications in China and is continuing to advance clinical research in multiple tumor fields. Its approved indications mainly include the following categories:

1.Classic Hodgkin lymphoma (cHL)

Tislelizumab is one of the first PD-1 inhibitors approved in China for the treatment of cHL patients who have failed second-line or higher systemic treatments. Studies have shown that it has a high objective response rate (ORR) and sustained response time in relapsed or refractory cHL.

2.Urothelial cancer (including bladder cancer)

For patients with locally advanced or metastatic urothelial cancer who have failed platinum-based chemotherapy or are not suitable for platinum-based chemotherapy, tislelizumab has shown good efficacy as a single agent, providing a new treatment option for these patients.

3.Non-small cell lung cancer (NSCLC)

The application of tislelizumab in the field of NSCLC is gradually expanding, especially in the treatment of advanced NSCLC in combination with chemotherapy. It has been supported by multiple research results. Currently, tislelizumab combined with paclitaxel + carboplatin regimen for the treatment of squamous NSCLC and pemetrexed + platinum regimen for the treatment of non-squamous NSCLC have been approved by the State Food and Drug Administration.

4.Hepatocellular carcinoma (HCC)

For patients with advanced hepatocellular carcinoma who have not received systemic treatment in the past, the treatment regimen of tislelizumab combined with bevacizumab-like drugs has also received positive clinical feedback and has entered late-stage trials in multiple international studies.

5.Esophageal squamous cell carcinoma (ESCC)

Tislelizumab, as a first-line immunotherapy regimen for the treatment of locally advanced or metastatic ESCC, has shown better survival benefits than traditional chemotherapy, further promoting its widespread use in the field of esophageal cancer.

In addition, tislelizumab has also conducted large-scale clinical studies in various solid tumors such as gastric cancer, renal cancer, and head and neck squamous cell carcinoma, with positive results.

3. Overview of clinical efficacy and safety

According to key clinical study data, tislelizumab has demonstrated a higher objective response rate (ORR) and a longer median overall survival (OS) in multiple indications. For example, in a phase III study of non-small cell lung cancer, the tislelizumab combination regimen significantly prolonged the progression-free survival (PFS) and overall survival (OS), the side effects are well controlled.

In terms of safety, the adverse reactions of tislelizumab are similar to other PD-1 drugs. Common immune-related side effects include fatigue, rash, decreased appetite, thyroid dysfunction, elevated liver enzymes and other immune-related side effects. Most adverse events are grade 1 to 2 and can be alleviated by suspending medication or using symptomatic treatments such as glucocorticoids.

It is worth noting that although immune-related adverse events are rare but may be serious, such as immune pneumonitis, enteritis, hepatitis, pancreatitis, etc., they require close monitoring and rapid response by clinicians.

Tislelizumab, as China’s innovative PD-1 inhibitor, has shown good efficacy in the treatment of multiple solid tumors and hematological tumors, and has gradually entered the global market. Its unique Fc engineering design and solid clinical data support its development path for a wide range of indications. In the future, tislelizumab is expected to play a key role in more combination treatment options and become an important pillar in the field of immunotherapy.

For patients, tislelizumab can be used not only as a single agent to treat certain advanced solid tumors, but also as part of a combination therapy to improve treatment response rates and prolong survival. Doctors' instructions should be strictly followed during use, and immune-related adverse reactions should be reviewed and monitored regularly to ensure safe and effective treatment.

Reference materials:https://www.drugs.com/donanemab.html

xa0